Cancer Research and Treatment

Original Article

Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules: Won Kyung Cho, Jae Myoung Noh, Yong Chan Ahn, Dongryul Oh, Hongryull Pyo; Cancer Res Treat. 2016;48(4):1187-1195. Published online March 9, 2016; DOI: https://doi.org/10.4143/crt.2015.391

Purpose
High dose definitive radiation therapy (RT) alone is recommended to patients with cT1-3N0 non-small cell lung cancer, who are unfit for surgery or stereotactic RT. This study was conducted to evaluate the clinical outcomes and cost-effectiveness following RT alone using two different modest hypofractionation dose schemes. Materials and Methods Between 2001 and 2014, 124 patients underwent RT alone. From 2001 till 2010, 60 Gy in 20 fractions was delivered to 79 patients (group 1). Since 2011, 60 Gy in 20 fractions (group 2, 20 patients), and 60 Gy in 15 fractions (group 3, 25 patients) were selectively chosen depending on estimated risk of esophagitis.
Results
At follow-up of 16.7 months, 2-year rates of local control, progression-free survival, and overall survival were 62.6%, 39.1%, and 59.1%, respectively. Overall survival was significantly better in group 3 (p=0.002). In multivariate analyses, cT3 was the most powerful adverse factor affecting clinical outcomes. Incidence and severity of radiation pneumonitis were not different among groups, while no patients developed grade 2 esophagitis in group 3 (p=0.003). Under current Korean Health Insurance Policy, RT cost per person was 22.5% less in group 3 compared with others. Conclusion The current study demonstrated that 60 Gy in 15 fractions instead of 60 Gy in 20 fractions resulted in comparable clinical outcomes with excellent safety, direct cost saving, and improved convenience to the patients with tumors located at ≥ 1.5 cm from the esophagus.

Citations

Citations to this article as recorded by

Outcome and safety of SBRT in centrally and ultra-centrally located lung tumours: A PRISMA-based systematic review and Meta-Analysis
Shari Wiegreffe, Sonja Adebahr, Tanja Schimek-Jasch, Julian Philipp Layer, Cas Stefaan Dejonckheere, Gustavo Renato Sarria, Davide Scafa, Youness Nour, Lara Caglayan, Dimos Baltas, Christos Moustakis, Nils Henrik Nicolay, Andreas Rimner, Anca-Ligia Grosu,
Clinical and Translational Radiation Oncology.2026; 59: 101151. CrossRef
Early Dynamics of Circulating Tumor DNA Following Curative Hypofractionated Radiotherapy Related to Disease Control in Lung Cancer
Kyungmi Yang, Jae Myoung Noh, Yeon Jeong Kim, Hongryull Pyo
Diagnostics.2025; 15(10): 1198. CrossRef
Radiotherapy in the management of lung oligometastases
V. Bourbonne, A. Lévy, J. Khalifa, D. Antoni, E. Blais, J. Darréon, C. Le Péchoux, D. Lerouge, P. Giraud, A. Marguerit, N. Pourel, F.-G. Riet, S. Thureau
Cancer/Radiothérapie.2024; 28(1): 36. CrossRef
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer
Kyungmi Yang, Jae Myoung Noh, Hye Yun Park, Hongseok Yoo, Sun Hye Shin, Hongryull Pyo
Frontiers in Oncology.2024;[Epub] CrossRef
Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC) Therapy
Zixuan Lyu, Chiming Wei
Cancer Research Journal.2024; 12(2): 27. CrossRef
Accelerated Hypofractionated Radiotherapy for Centrally Located Lung Tumours Not Suitable for Stereotactic Body Radiotherapy or Chemoradiotherapy
K.L. Zeng, I. Poon, Y. Ung, M. Tsao, L. Zhang, A. Cumal, A.V. Louie, P. Cheung
Clinical Oncology.2023; 35(2): e173. CrossRef
An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
Izabela Zarębska, Maciej Harat
Thoracic Cancer.2023; 14(28): 2813. CrossRef
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer
Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh
Life.2022; 12(2): 292. CrossRef
Prospective Study of Proton Therapy for Lung Cancer Patients with Poor Lung Function or Pulmonary Fibrosis
Jae Myoung Noh, Hongseok Yoo, Woojin Lee, Hye Yun Park, Sun Hye Shin, Hongryull Pyo
Cancers.2022; 14(6): 1445. CrossRef
Hypofractionated Postoperative Radiation Therapy for Breast Cancer – Do We Need More Evidence or Adapted Reimbursement Policies?
Monica-Emilia Chirilă, Ivica Ratosa, Gustavo Nader Marta, Philip Poortmans
Journal of Medical and Radiation Oncology.2021; 1(1): 83. CrossRef
Radiotherapy for Lung Cancer During the COVID Pandemic – A Narrative Review of Practical Recommendations
Prasenjit Chatterjee, Jibak Bhattacharya, Tanmay Ghosh, Biplap Sarkar, Monica-Emilia Chirilă, Sushmita Roy Chowdhury, Syamasis Bandyopadhyay, Jayaprakash Agarwal
Journal of Medical and Radiation Oncology.2021; 1(1): 99. CrossRef
Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic
C. Faivre-Finn, J.D. Fenwick, K.N. Franks, S. Harrow, M.Q.F. Hatton, C. Hiley, J.J. McAleese, F. McDonald, J. O'Hare, C. Peedell, T. Pope, C. Powell, R. Rulach, E. Toy
Clinical Oncology.2020; 32(8): 481. CrossRef
Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak
Zhongxing Liao, Eleonor Rivin del Campo, Ahmed Salem, Qingsong Pang, Hui Liu, Jose Luis Lopez Guerra
Lung Cancer.2020; 146: 230. CrossRef
Radiation dose intensity and local tumour control of non-small cell lung cancer: A radiobiological modelling perspective
M Alaswad, C Kleefeld, M Foley
Journal of Physics: Conference Series.2019; 1248(1): 012071. CrossRef

13,268 View
249 Download
11 Web of Science
14 Crossref

First
Prev
Page of 1
Next
Last

Search